Hyderabad, Feb. 12 -- Hyderabad based Biological E. Limited (BE) on Thursday announced a major milestone in the global fight against polio, with the World Health Organization (WHO) granting Phase II Pre-Qualification (PQ) for its Novel Oral Polio Vaccine type 2 (nOPV2).
Phase II Pre-Qualification covers both Drug Substance and Drug Product manufactured at BE, completing the full manufacturing chain for nOPV2 at a single integrated site, the pharma company said in a release here. This expands BE's WHO-qualified manufacturing scope beyond Phase I, under which the company received PQ in June 2024 for drug product manufacturing using externally supplied drug substance.
BE has already manufactured and supplied 700 million doses of nOPV2 to the...